本帖最后由 老马 于 2012-1-13 21:20 编辑
) f' V" X' H3 |& c7 a5 t, _; `8 w+ x9 s5 y5 D
爱必妥和阿瓦斯丁的比较
5 J4 k' f7 A) l* Q2 c5 r
! @% z H: \" }" Y/ J
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
3 I" e2 I( u: v7 l
& ~, ^2 W/ O7 P! ~6 G; G1 ]
0 |& X. A5 {+ ^% X/ l$ b
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& @# N+ }& v P/ p# F( x; a% f! i
==================================================
3 s2 e0 ^; ~5 R" T. _Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ B" F$ e5 w* J/ U S
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 R# T$ A" K% d1 |( b* BResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- Y5 `5 ~1 F3 A8 N
|